Perrigo Company plc (PRGO) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong EPS growth and operational improvements are offset by declining sales and margins. The Q&A reveals management's optimism for 2026 and beyond, but uncertainties around specific business segments persist. The strategic reviews and divestitures indicate potential future improvements, but immediate impacts are unclear. Overall, the sentiment is balanced, suggesting a neutral stock price movement in the short term.
Key Financial Performance
All-In Operating Income Grew by 2% year-over-year in 2025. This growth was attributed to operational rigor and disciplined cost management.
All-In EPS Increased by 7% year-over-year, finishing at $2.75. This was in line with revised guidance and driven by operational improvements and cost management.
CORE Perrigo Operating Income Increased by 7% year-over-year in 2025. This was due to operational rigor and cost-saving initiatives.
CORE Perrigo EPS Increased by 14% year-over-year in 2025. This was driven by operational improvements and cost-saving measures.
CORE Organic Net Sales (Q4 2025) Declined by 2% year-over-year. This was due to market weakness despite strong share gains.
CORE Operating Income (Q4 2025) Declined by $4 million or 2% year-over-year. This was attributed to market weakness and lower net sales.
Infant Formula Net Sales Declined by roughly 25% in Q4 2025 and 10% for the full year. This was due to lower contract manufacturing and reduced distribution of the Good Start brand.
Project Energize Savings Generated $320 million in benefits in 2025. This contributed to improvements in operating income and EPS.
Cash on Balance Sheet (End of 2025) $532 million. This was supported by $175 million in Q4 operating cash flow and $239 million total for the year.
Net Leverage Ratio (End of 2025) 4x, slightly above projections due to currency translation on gross debt and lower cash balances.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Innovation pipeline: Tripled in value compared to the prior year, indicating a strong focus on new product development.
Infant formula: Stabilized supply with service levels above 90%, despite slowed demand recovery and intensified competition.
Market share gains: Achieved solid market share gains in both the U.S. and Europe, reversing years of decline in the U.S. and gaining share in key European brands.
Retailer partnerships: Secured over $100 million in new distribution and competitive takeaways, strengthening partnerships with retailers.
Three-S Plan: Focused on simplifying, streamlining, and strengthening the business, including stabilizing store brand business and executing efficiency initiatives like Project Energize and supply chain reinvention, yielding $320 million in benefits.
Operational enhancement program: Introduced a new 2-year program targeting $80-$100 million in annualized pretax savings, including a 7% global workforce reduction and cost reductions in supply chain and distribution.
Portfolio focus: Announced the sale of the Dermacosmetics business and continued assessment of Infant Formula and Oral Care roles in the portfolio.
New reporting segments: Transitioning to new segments (Self-care, Specialty Care, Infant Formula) starting Q1 2026 to align with the global operating model and enhance transparency.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Infant Formula Business Challenges: The infant formula business continues to face structural challenges, including slowed demand recovery and intensified competition, which have negatively impacted financials and outlook.
Market Conditions: Soft market environment and negative OTC market consumption trends, particularly in the U.S., have led to declining sales and inventory adjustments by retailers.
Plant Underabsorption: Lower sales volumes in 2025 have resulted in significant underabsorption at manufacturing plants, leading to an unfavorable EPS impact of approximately $0.60 for 2026.
Goodwill Impairment: A $1.3 billion goodwill impairment charge in 2025 and potential additional charges of up to $350 million in Q1 2026 reflect underperformance of historically acquired businesses.
Operational Cost Pressures: Higher costs from temporary OTC plant underabsorption, increased advertising and promotion expenses, and the reset of variable incentive plans are expected to pressure margins in 2026.
Regulatory and Antitrust Clearance: The sale of the Dermacosmetics business is pending final antitrust clearance, which could delay the transaction and associated debt reduction plans.
Supply Chain and Distribution Network: Efforts to streamline operations and reduce costs include a global workforce reduction of approximately 7% and operational cost reductions in the supply chain and distribution network, which may face execution risks.
Economic Uncertainty: Soft category consumption and economic uncertainties in both the U.S. and Europe are impacting consumer demand and overall market performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Outlook for CORE Perrigo: Organic net sales growth is expected to range from -3.5% to +0.5% compared to 2025. CORE EPS is projected to be between $2.25 and $2.55. Gross margin is anticipated to be between 39% and 40%, with operating margin expected between 15% and 16%. Temporary cost pressures from OTC plant under absorption are expected to dissipate over the next 12 months.
2026 Outlook for All-In Perrigo: Net sales growth is expected to range from -5.5% to -1.5%. Gross margin is projected to be between 36.5% and 37.5%, with operating margin between 12.5% and 13.5%. EPS is expected to range from $2 to $2.30.
Operational Enhancement Program: A new 2-year program is expected to deliver annualized pretax savings of $80 million to $100 million, with approximately 80% of the savings realized in 2026. This includes a global workforce reduction of approximately 7% and operational cost reductions in the supply chain and distribution network. Total costs to achieve these savings are estimated at $80 million to $90 million.
Market Conditions and Sales Projections: OTC market consumption is expected to remain negative in the first half of 2026, with a potential improvement in the second half. U.S. OTC market sales are down 5.1% over the last 13 weeks compared to the prior year. Retailers are adjusting inventory levels to match current demand, which will impact first-quarter results.
Strategic Focus for 2026: The company aims to grow share in key brands, deliver its innovation pipeline, drive U.S. store brand demand generation, execute operational and cost-saving programs, and continue portfolio assessment efforts. Geographic expansion for priority brands and continued distribution gains are also planned.
Cash Flow and Leverage: Operating cash flow conversion is expected to remain in the mid-60% range for 2026. Net leverage is projected to end the year roughly in line with or slightly better than 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Policy: The company reiterated its commitment to returning value to shareholders through its dividend policy. However, no specific changes or updates to the dividend program were mentioned.
Share Repurchase Program: There was no mention of a share repurchase program or any related activities in the transcript.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is driving the second half improvement in 2026 and what is needed for OTC categories to stabilize and grow?
A:The decline is seen as transitory, caused by factors like household reduction in certain subcategories, trade-down to smaller units, rollbacks from national brands, and lack of price increases. The second half improvement is driven by factors such as growing share, store brand OTC growth, innovation (60% of value in the second half), geographic expansion (65% in the second half), distribution gains, and demand generation efforts.
Q:What is the update on liquidity, leverage position, and the ability to reinvest in the business?
A:The company’s capital allocation priorities remain unchanged: investing in the business, reducing leverage, and returning value to shareholders through dividends. The Dermacosmetics sale proceeds will be used to reduce debt. 2026 is seen as a transitory year with challenges in free cash flow, but improvements are expected in 2027 as operational enhancement programs sustain over time.
Q:How is the recovery of OTC margins expected to progress?
A:The under-absorption impacting margins in 2026 is transitory, reflecting the softening in the second half of the previous year. Despite share gains, high inventory costs have impacted margins. The market is expected to normalize in the second half of 2026 and into 2027, leading to margin improvements.
Q:What is the outlook for the Infant Formula business and its strategic review?
A:The strategic review is ongoing, assessing options like optimizing operations, partnerships, or divestments. The business is expected to achieve low to mid-single-digit revenue growth in 2026, clearing lower-margin inventory and restoring gross profit to 2024-2025 levels. Plant optimization and aligning capacity with long-term volume are key to improving margins and cash flow.
Q:Which CORE sales categories are performing better or worse, and what is driving the guidance towards the lower end?
A:Preventative categories like VMS and digestive wellness are performing better, while cough/cold and certain subsegments of pain (e.g., pill dosing) are underperforming. Allergy and topical creams are doing well. The guidance towards the lower end is driven by weak performance in cough/cold and pain pill categories.
Q:What are the company’s long-term leverage goals and dividend priorities?
A:The company aims to keep leverage in line or slightly better than 2025 levels for 2026, with a target of below 3x leverage over the next 2-3 years. Dividends remain a priority, but capital allocation will be assessed based on what delivers the best sustainable shareholder return.
Q:What is the working capital situation for the Infant Formula business?
A:The business has significant working capital tied up in high inventory levels built in the prior year. Low to mid-single-digit net sales growth in 2026 is expected to deplete inventory and normalize working capital levels.
Q:What was the response to price investments in CSCI?
A:Price investments in CSCI are an annual effect due to competition and supplier substitution. The company has implemented systemic programs to address this, including productivity, mix, innovation, and expanding into profitable adjacencies. These efforts aim to protect and enhance gross profit and operating income margins.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the progress of the strategic review for the Infant Formula business, stating it was too early to comment. Additionally, they did not provide precise data on the working capital associated with the Infant Formula business or the exact impact of price investments in CSCI.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CORE Perrigo
Eduardo
OTC market
Perrigo CORE
Perrigo future
Perrigo sale
absorption
consumer momentum
contract manufacturing
cough season
debt
decline
demand generation
enhancement program
formula divestiture
gain sale
goodwill impairment
goodwill reporting
impact
impairment charge
level demand
market condition
market environment
noncash
outlook CORE
priority
productivity
progress Plan
reality
reduction
reporting segment
reporting unit
result CORE
result reporting
sale contract
sale volume
term value
underabsorption
PRGO Transcript
Perrigo Company plc (PRGO) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call summary indicates a positive sentiment with a 5% revenue increase, 10% rise in adjusted operating income, and improved gross margin. Despite risks associated with regulatory hurdles and strategic execution, these financial metrics and operational efficiencies suggest a favorable outlook. The lack of negative sentiment in the Q&A and the strong demand in the consumer health segment further support a positive stock price movement prediction over the next two weeks.
Perrigo Company plc (PRGO) Presents at UBS Global Consumer and Retail Conference Transcript
Neutral3-11
Perrigo Company plc (PRGO) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call presents a mixed picture: strong EPS growth and operational improvements are offset by declining sales and margins. The Q&A reveals management's optimism for 2026 and beyond, but uncertainties around specific business segments persist. The strategic reviews and divestitures indicate potential future improvements, but immediate impacts are unclear. Overall, the sentiment is balanced, suggesting a neutral stock price movement in the short term.
Perrigo Company plc (PRGO) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reveals mixed signals. Basic financial performance shows some decline in gross profit and margin, but EPS grew slightly. Product development is hindered by slower-than-expected recovery in Infant Formula. Market strategy shows potential with new SKUs, though facing execution challenges. Expenses are managed well, but tariffs are a concern. The shareholder return plan remains stable. Q&A highlights management's unclear responses on critical issues, adding uncertainty. Overall, the sentiment is neutral, with no significant catalysts or detractors to drive the stock price significantly in either direction.
PRGO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
